

16 May 2019



PACIFIC EDGE FULL YEAR RESULT TO BE ANNOUNCED 29 MAY 2019

Pacific Edge Limited (NZX:PEB) advises that it intends to announce its full year result for the financial year ended 31 March 2019 on Wednesday 29 May 2019, prior to 10am NZST.

This will be followed by an analyst and investor conference call with Pacific Edge Chief Executive, David Darling and Chief Financial Officer, Kate Rankin. The conference call is scheduled to begin at 10.30am NZST.

To attend the conference call, participants will need to dial into one of the numbers below at least 5-10 minutes prior to the scheduled call time and identify yourself to the operator. When prompted, please quote the **confirmation code: 5579261**.

The results presentation will be released to the NZX and can also be streamed live by following the link. Please note that you need to dial in to hear the audio: <https://slideassist.webcasts.com/starthere.jsp?ei=1243863>.

Media are invited to contact the company directly for an interview with management.

A recording of the conference call will be made available within 48 hours in the Investor section on the Pacific Edge website.

If you have any queries regarding the results announcement or the conference call, please contact Stacey Stanley on 03 479 5807 or stacey.stanley@pelnz.com.

Dial toll free from NZ:	0800 423 970
Dial toll free from Australia:	1800 573 793
Dial toll free from USA:	866 548 4713
Dial toll free from Singapore:	800 186 5107
Dial toll free from Hong Kong:	800 961 105

ENDS

Approved for release by:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its non-invasive, simple to use and accurate Cxbladder tests enable the detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder provides actionable results and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder tests globally and has two wholly owned accredited laboratories in New Zealand and the USA. The company's products have been tested and validated in multiple international clinical studies.

ABOUT Cxbladder Triage

Cxbladder Triage accurately identifies patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial cancer.

ABOUT Cxbladder Detect

Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy. Is often used in conjunction with Cxbladder Triage to provide greater rule-out and resolution of patients who have UC.

ABOUT Cxbladder Monitor

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial cancer. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.